CYDY
CytoDyn Inc.0.3200
+0.0200+6.67%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
405.07MP/E (TTM)
-Basic EPS (TTM)
-0.02Dividend Yield
0%Recent Filings
8-K
CytoDyn raises $17.5M via units
CytoDyn wrapped a private placement on February 27, 2026, selling 81.4 million units—each one common share plus warrant—at $0.2153, netting $17.5 million cash. Direct sales and SEPA draws added $1.3 million more; note exchanges swapped $1.5 million principal for 5.9 million shares. Dilution hit over 5% of January shares. Warrants tempt future overhang.
10-Q
Q2 FY2026 results
CytoDyn posted a Q2 operating loss of $21.7M, up from $3.7M last year, driven by a $16.6M legal settlement loss while R&D climbed to $3.3M from $1.4M on clinical trials. Net loss hit $22.6M or $(0.02) per share on 1.26B shares, consistent with diluted figures as losses excluded dilution. Cash drained to $5.0M from $11.9M, with $6.8M operating burn; $27.2M convertible notes (6%, due Apr 2026) plus $15.0M accrued interest loom large. Cash is tight. Ongoing derivative suits add uncertainty.
8-K
CytoDyn settles class action
CytoDyn struck an agreement in principle on November 23, 2025, to settle its securities class action in Washington federal court for $500,000 cash and 49 million common shares. Dismissal hinges on final documentation and court approval. No liability admitted. Litigation could still sting financially if talks collapse.
8-K
Authorized shares increased 500M
8-K
CytoDyn secures $30M equity line
CytoDyn inked a Standby Equity Purchase Agreement with Yorkville on November 3, 2025, securing access to up to $30M in funding over 36 months by selling common stock at 98% of the lowest VWAP over a three-day pricing period. Advances cap at 100% of prior five-day average volume; Yorkville's ownership stays under 4.99%. Proceeds target working capital and debt repayment. Dilution looms large.
CDTX
Cidara Therapeutics, Inc.
220.05-0.05
CERO
CERo Therapeutics Holdings, Inc
0.09-0.01
CLDI
Calidi Biotherapeutics, Inc.
1.30-0.03
CLYM
Climb Bio, Inc.
4.62+0.81
CYBN
Cybin Inc.
6.66+0.00
CYTOF
Altamira Therapeutics Ltd.
0.07+0.00
EDSA
Edesa Biotech, Inc.
1.49-0.00
GDTC
CytoMed Therapeutics Limited
1.62+0.02
LIMN
Liminatus Pharma, Inc.
0.78+0.02
YDES
YD Bio Limited
12.62+0.22